Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

Completed · Phase 1

Conditions studied: Hepatitis C

In brief

The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.

Key facts

Study ID

NCT00124215

Run by

GlobeImmune

People needed

48

Starts

2005-06-01

Expected to finish

2010-02-01

Last updated by the study team

2010-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with chronic hepatitis C virus infection including treatment naive subjects as well as subjects who are partial responders and relapsers to prior interferon therapy
• >18 years of age
• Negative skin test for hypersensitivity to saccharomyces cerevisiae.

You may not qualify if…

• Non-responders to previous interferon treatments
• Cirrhosis
• HCV treatment within 3 months
• Hepatitis B infection
• HIV infection

Where it is running

• Huntington Medical Research Institutes — Pasadena, California, United States
• University of Colorado Health Sciences Center — Denver, Colorado, United States
• University of Miami — Miami, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Weill Medical College of Cornell University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.